XML 45 R13.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Financial Instruments | 9 Months Ended
--- | ---
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract] |
Financial Instruments | The following table summarizes our financial assets with maturities of less than 90 days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:
(In millions) |  | As of September 30, 2022 |  | As of December 31, 2021
Commercial paper |  | $ | 3.2 |  |  | $ | 247.6 |
Overnight reverse repurchase agreements |  | 115.5 |  |  | 200.0 |
Money market funds |  | 3,070.6 |  |  | 901.6 |
Short-term debt securities |  | 2.5 |  |  | 283.0 |
Total |  | $ | 3,191.8 |  |  | $ | 1,632.2 |
The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. Our marketable equity securities (gains) losses are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:
|  | As of September 30, 2022
(In millions) |  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Fair Value
Marketable debt securities |  |  |  |  |  |  |  |
Corporate debt securities: |  |  |  |  |  |  |  |
Current |  | $ | 833.6 |  |  | $ | — |  |  | $ | (6.9) |  |  | $ | 826.7 |
Non-current |  | 400.5 |  |  | — |  |  | (8.1) |  |  | 392.4 |
Government securities: |  |  |  |  |  |  |  |
Current |  | 412.1 |  |  | 0.1 |  |  | (3.5) |  |  | 408.7 |
Non-current |  | 298.8 |  |  | — |  |  | (5.5) |  |  | 293.3 |
Mortgage and other asset backed securities: |  |  |  |  |  |  |  |
Current |  | 0.1 |  |  | — |  |  | — |  |  | 0.1 |
Non-current |  | 177.6 |  |  | — |  |  | (3.0) |  |  | 174.6 |
Total marketable debt securities |  | $ | 2,122.7 |  |  | $ | 0.1 |  |  | $ | (27.0) |  |  | $ | 2,095.8 |
Marketable equity securities |  |  |  |  |  |  |  |
Marketable equity securities, non-current |  | $ | 1,133.8 |  |  | $ | — |  |  | $ | (237.8) |  |  | $ | 896.0 |
Total marketable equity securities |  | $ | 1,133.8 |  |  | $ | — |  |  | $ | (237.8) |  |  | $ | 896.0 |
|  | As of December 31, 2021
(In millions) |  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Fair Value
Marketable debt securities |  |  |  |  |  |  |  |
Corporate debt securities: |  |  |  |  |  |  |  |
Current |  | $ | 723.6 |  |  | $ | 0.1 |  |  | $ | (0.3) |  |  | $ | 723.4 |
Non-current |  | 385.4 |  |  | 0.2 |  |  | (0.8) |  |  | 384.8 |
Government securities: |  |  |  |  |  |  |  |
Current |  | 817.0 |  |  | — |  |  | (0.4) |  |  | 816.6 |
Non-current |  | 377.0 |  |  | 0.1 |  |  | (1.0) |  |  | 376.1 |
Mortgage and other asset backed securities: |  |  |  |  |  |  |  |
Current |  | 1.1 |  |  | — |  |  | — |  |  | 1.1 |
Non-current |  | 131.8 |  |  | — |  |  | (0.7) |  |  | 131.1 |
Total marketable debt securities |  | $ | 2,435.9 |  |  | $ | 0.4 |  |  | $ | (3.2) |  |  | $ | 2,433.1 |
Marketable equity securities |  |  |  |  |  |  |  |
Marketable equity securities, current |  | $ | 33.9 |  |  | $ | 9.9 |  |  | $ | — |  |  | $ | 43.8 |
Marketable equity securities, non-current |  | 1,133.1 |  |  | 151.0 |  |  | (279.4) |  |  | 1,004.7 |
Total marketable equity securities |  | $ | 1,167.0 |  |  | $ | 160.9 |  |  | $ | (279.4) |  |  | $ | 1,048.5 |
Summary of Contractual Maturities: Available-for-Sale Debt Securities The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:
|  | As of September 30, 2022 |  | As of December 31, 2021
(In millions) |  | Estimated Fair Value |  | Amortized Cost |  | Estimated Fair Value |  | Amortized Cost
Due in one year or less |  | $ | 1,235.5 |  |  | $ | 1,245.8 |  |  | $ | 1,541.1 |  |  | $ | 1,541.7 |
Due after one year through five years |  | 848.3 |  |  | 864.0 |  |  | 868.2 |  |  | 870.2 |
Due after five years |  | 12.0 |  |  | 12.9 |  |  | 23.8 |  |  | 24.0 |
Total marketable debt securities |  | $ | 2,095.8 |  |  | $ | 2,122.7 |  |  | $ | 2,433.1 |  |  | $ | 2,435.9 |
The average maturity of our marketable debt securities classified as available-for-sale as of September 30, 2022 and December 31, 2021, was approximately 9 months and 10 months, respectively. Proceeds from Marketable Debt Securities The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:
|  | For the Three Months Ended September 30, |  | For the Nine Months Ended September 30,
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Proceeds from maturities and sales |  | $ | 1,643.2 |  |  | $ | 575.4 |  |  | $ | 3,104.7 |  |  | $ | 2,028.1 |
Realized gains |  | — |  |  | 0.1 |  |  | — |  |  | 0.4 |
Realized losses |  | 7.9 |  |  | 0.5 |  |  | 9.3 |  |  | 1.7 |
Realized losses for the three and nine months ended September 30, 2022 and 2021, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Strategic Investments As of September 30, 2022, our strategic investment portfolio was comprised of investments totaling $948.5 million which are included in investments and other assets in our condensed consolidated balance sheets. As of December 31, 2021, our strategic investment portfolio totaled $1,110.3 million and was included in other current assets and investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, Fair Value Measurements, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. The decrease in our strategic investment portfolio as of September 30, 2022, was primarily due to a decrease in the fair value of our investments in Denali and Sangamo common stock. For additional information on our investments in Denali, Sage and Sangamo common stock, please read Note 18, Collaborative and Other Relationships, to our consolidated financial statements included in our 2021 Form 10-K.

X
- Definition The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 + Details
Name: | us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration